CustomCustomCustomCustomCustomCustom
17 01, 2024

Analysis of extracellular vesicle microRNA profiles reveals distinct blood and lymphatic endothelial cell origins

2024-01-17T11:03:50+01:00January 17th, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, microRNA, microRNA services, microRNAs|Comments Off on Analysis of extracellular vesicle microRNA profiles reveals distinct blood and lymphatic endothelial cell origins

We want to draw your attention to the latest collaborative publication by TAmiRNA scientist Marianne Pultar: “Analysis of extracellular vesicle microRNA profiles reveals distinct blood and lymphatic endothelial cell origins” published in the Journal of Extracellular Biology. By applying TAmiRNA´s unique small RNA-seq and RNA-seq workflows, this study provides important insights into the secretory behavior of endothelial cell-derived extracellular vesicles (EVs) and their microRNA cargo. In future, these findings can support the identification and development of non-invasive and cell-type specific biomarkers in liquid biopsis. Click here to learn more about our EV service click here to read the paper

Read More
10 01, 2024

TAmiRNA partners with Techtum Lab

2024-01-10T09:45:03+01:00January 10th, 2024|microRNA, microRNA services, microRNAs, miND spike ins, NGS, PCR testing service, smallRNA, Techtum Lab|Comments Off on TAmiRNA partners with Techtum Lab

TAmiRNA has entered an exclusive distribution agreement with Techtum Lab for the sales of their products in the Nordics. Techtum Lab is a full service supplier and partner to clinical and research molecular biology laboratories and looks back at >45 years of experience in the Nordic region. TAmiRNA complements Techtum’s NGS portfolio with the miND Spike-Ins, a unique set of controls for small RNA sequencing experiments. Furthermore, Techtum partners with TAmiRNA to make customized RNA sequencing services accessible to those customers who are looking for external support with analysing their sample’s RNA content.

Read More
22 11, 2023

TAmiRNA meets Japanese Pharma to present microRNA Biomarker Discovery Solutions

2023-11-22T11:22:16+01:00November 22nd, 2023|biomarker, biomarkers, exosomes, extracellular vesicle, microRNA, microRNA services, microRNAs, NGS, PCR testing service, SPI|Comments Off on TAmiRNA meets Japanese Pharma to present microRNA Biomarker Discovery Solutions

Matthias Hackl, CEO/CSO of TAmiRNA, visited Japan between November 11th and 18th to join Summit Pharmaceutical international to introduce TAmiRNA to 12 medium- and large-size pharmaceutical companies. Matthias presented information on microRNA and mRNA biomarker discovery in liquid biopsies using TAmiRNA´s unique miND® pipeline for absolute quantification of microRNAs. In addition, Matthias joined a seminar on “Manufacturing and omic-based characterization of extracellular vesicles as drug products” organized by the local partner Summit Pharmaceutical International. In his talk, Matthias explained to >70 representatives from Japanese Universities and Pharmaceutical industry TAmiRNA’s the advantages of full molecular characterization of exosomes and extracellular vesicles (EVs) to determine EV composition, consistency, and mode-of-action.

Read More
31 01, 2023

We are proud to announce our ISO 13485:2016 certification

2023-03-10T08:28:14+01:00January 31st, 2023|biomarkers, ISO 13485, microRNA, quality, smallRNA|Comments Off on We are proud to announce our ISO 13485:2016 certification

Today we announce that TAmiRNA has received ISO 13485:2016 certification for its Medical Device and Quality Management System after successfully completing the audit through Germany-based notified body MDC. This ISO certification indicates that TAmiRNAs quality management system meets the most current regulatory requirements applicable to the medical device industry. "We are very proud of this certification as it demonstrates the commitment of our team to meet customer and international regulatory expectations," said Matthias Hackl, Co-Founder and CEO of TAmiRNA. ISO 13485:2016 is an internationally recognized quality systems standard tailored to the development and manufacturing of medical devices, including in-vitro diagnostic tests. This certification represents an important milestone for our company, and reflects our rigorous and risk-based approach [...]

Read More
30 01, 2023

Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects

2023-03-10T08:28:49+01:00January 30th, 2023|biomarkers, diagnose disease, extracellular vesicle, microRNA, platelet-associated miRNAs, smallRNA, thrombomiR, treatment monitoring|Comments Off on Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects

We want to draw your attention to our most recent publication where we investigated platelet-enriched miRNAs (thrombomiRs) as suitable candidates for monitoring antiplatelet therapy. The study provides evidence that thrombomiRs are promising biomarker candidates for monitoring the extent of platelet inhibition. This could enable stratification of patients depending on their response to antiplatelet therapy and guide treatment decisions. click here to read the paper

Read More
17 01, 2023

Biogenity Joins Forces with TAmiRNA

2023-03-10T08:29:26+01:00January 17th, 2023|biomarkers, diagnose disease, microRNA, NGS, smallRNA, treatment monitoring|Comments Off on Biogenity Joins Forces with TAmiRNA

The collaboration between Biogenity and TAmiRNA is a big step towards further enabling our clients to identify new biomarkers that can be used to diagnose disease, monitor treatment response, and predict patient outcomes. And an important step to advance omics research and bring better healthcare to future generations. click here to read the press release

Read More
28 10, 2022

miND spike-in

2023-03-10T10:13:11+01:00October 28th, 2022|microRNA, NGS, smallRNA|Comments Off on miND spike-in

TAmiRNA has launched an innovative NGS technology for absolute quantitation of miRNAs and other small RNAs , the miND® (microRNA Next-Generation Sequencing Discovery) spike-in. The miND® spike-in has been developed for small RNA sequencing experiments and absolute quantitation of microRNAs in any biological matrix and species, overcoming previous challenges of quality control and difficulty in achieving  absolute quantitation of miRNAs across different biological matrix and species. click here for more Information on the miND spike-ins

Read More
26 05, 2022

hepatomiR kit

2023-03-10T10:14:05+01:00May 26th, 2022|biomarkers, hepatomiR kit, Liver disease, microRNA|Comments Off on hepatomiR kit

TAmiRNA has launched its latest hepatomiR® CE-IVD testing kit that can measure levels of three important liver-enriched microRNAs (liver miRNAs) in human blood to determine a patient’s liver function. TAmiRNA’s microRNA-based hepatomiR® kit is worldwide the first approved CE-IVD test to measure microRNA liver biomarkers in human plasma. The new microRNA-based hepatomiR® technology represents a milestone previously restricted to research use only (RUO) testing. click here for more Information on the hepatomiR-kit

Read More
2 03, 2022

miRNA NGS Discovery pipeline – miND

2023-03-10T10:13:34+01:00March 2nd, 2022|biomarkers, microRNA, NGS|Comments Off on miRNA NGS Discovery pipeline – miND

TAmiRNA present microRNA Next-Generation-Sequencing Discovery Assay (miND), a novel panel of exogenous small RNA spike-in controls that enables quality control and absolute quantitation of NGS data. Eager to learn more - have a look at our two new publications! click here for more Information on the novel wet-lab small RNA-seq workflow and here for more insights into the bioinformatic pipeline

Read More
1 10, 2020

Dr. Michael Nodine´s Spike-in technology is nominated for a Houska prize

2023-03-10T10:28:48+01:00October 1st, 2020|biomarker, microRNA, microRNA services, Personalized medicine, safety, test service|Comments Off on Dr. Michael Nodine´s Spike-in technology is nominated for a Houska prize

The “Houska“ Prize, awarded annually by the B&C Foundation, is Austria´s biggest private award for applied research. Dr. Michael Nodine, Gregor Mendel Institute of Molecular Plant Biology (GMI), was nominated for his work on the development of methods for nucleic acid quantification. A major issue they encountered was the lack of absolute quantification of small RNA levels, making the comparison between tissues difficult. To overcome this problem, Michael and his team, developed a set of synthetic small RNA Spike-Ins that could be added to these tissue samples. This technology allows us to accurately quantify the levels of different small RNAs that could play a role in several human diseases, ranging from cancer to cardiovascular disease. In 2019, GMI [...]

Read More
© Copyright TAmiRNA 2019 - 
Go to Top